triumph 1 trial retatrutide 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide hits 28.3% weight loss

Lotte Bjerre Knudsen, the legendary Chief Scientific Advisor at Novo Nordisk and the driving force behind the development of semaglutide (recently recognized with the 2025 Breakthrough Prize), took the stage

doi: 10.1016/j.bbr.2010.05.033 43 VakalopoulosC

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) are used for type 2 diabetes and obesity management by mimicking natural GLP-1 hormone

Traditional methods like strict diets, intensive workouts, and injections are difficult to maintain and often ineffective

Explore the 20mg Retatrutide Pen (VLS): Disclaimer This content is for informational and research purposes only